Nevertheless, numerous studies have demonstrated the persistence of CML leukemic cells in the bone marrow (BM) niche following treatment, even in patients with undetectable levels of the BCR::ABL1 transcript by RT-qPCR. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.